Related Experiment Video
Updated: Aug 15, 2026
07:25
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Research progress on hepatitis B surface antigen decline and clearance
Yi-Fan Guo1,2, Meng-Qi Sun1,3, Yi-Zhe Zhang1,3
1Senior Department of Hepatology, the Chinese PLA General Hospital, Beijing 100039, China.
Iliver
|August 14, 2026
Summary
Achieving hepatitis B surface antigen (HBsAg) loss is key for a functional cure in chronic hepatitis B (CHB). This signifies reduced liver damage and lower liver cancer risk, improving patient prognosis.
Area of Science:
- Hepatology
- Immunology
- Virology
Background:
- Chronic hepatitis B (CHB) is a leading cause of liver cirrhosis and hepatocellular carcinoma (HCC), especially in China.
- The goal of CHB treatment is shifting from viral suppression to functional cure, marked by HBsAg loss.
Purpose of the Study:
- To review HBsAg's role in CHB pathogenesis and prognosis.
- To explore immune mechanisms driving HBsAg decline and clearance.
- To discuss predictive models and strategies for achieving HBsAg clearance.
Main Methods:
- Literature review of recent domestic and international advances.
- Analysis of HBsAg dynamics during antiviral therapy.
- Examination of immunologic mechanisms and predictive models.
Main Results:
- HBsAg clearance correlates with reduced liver inflammation, fibrosis regression, and decreased HCC risk.
- Understanding immune responses is crucial for HBsAg decline.
- Predictive models and targeted therapies are emerging.
Conclusions:
- HBsAg loss is a critical marker for favorable long-term outcomes in CHB.
- Integrated immunologic understanding is vital for functional cure.
- Further research is needed for standardized and precision CHB management.
